A role for HPV16 E5 in cervical carcinogenesis
By: Maufort JP, Shai A, Pitot HC, Lambert PF.

Department of Oncology and the McArdle Laboratory for Cancer Research, University of Wisconsin School of Medicine and Public Health, Madison, WI 53706, USA.
Cancer Res. 2010 Apr 1; 70(7):2924-31. Epub 2010 Mar 23.

Abstract

A subset of the mucosotropic human papillomaviruses (HPV), including HPV16, are etiologic agents for the vast majority of cervical cancers, other anogenital cancers, and a subset of head and neck squamous cell carcinomas. HPV16 encodes three oncogenes: E5, E6, and E7. Although E6 and E7 have been well-studied and clearly shown to be important contributors to these cancers, less is known about E5. In this study, we used E5 transgenic mice to investigate the role of E5 in cervical cancer. When treated for 6 months with estrogen, a cofactor for cervical carcinogenesis, E5 transgenic mice developed more severe neoplastic cervical disease than similarly treated nontransgenic mice, although no frank cancers were detected. In addition, E5 when combined with either E6 or E7 induced more severe neoplastic disease than seen in mice expressing only one viral oncogene. Prolonged treatment of E5 transgenic mice with exogenous estrogen uncovered an ability of E5 to cause frank cancer. These data indicate that E5 acts as an oncogene in the reproductive tracts of female mice.

PMCID: PMC2848882 [Available on 2011/4/1]; PMID: 20332225 [PubMed - indexed for MEDLINE] Source: National Library of Medicine.






* Albert Einstein College of Medicine has been
awarded Acceditation with Commendation by
the ACCME

Copyright 2025 InterMDnet | Privacy Policy | Disclaimer | System Requirements